A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children

Sponsor
Jiangsu HengRui Medicine Co., Ltd. (Industry)
Overall Status
Completed
CT.gov ID
NCT04200235
Collaborator
(none)
48
1
2
7
6.8

Study Details

Study Description

Brief Summary

The study is being conducted to evaluate the efficacy, safety and the population pharmacokinetic characteristics of dexmedetomidine hydrochloride nasal spray for preoperative sedation in children

Condition or Disease Intervention/Treatment Phase
  • Drug: Dexmedetomidine hydrochloride nasal spray
  • Drug: Dexmedetomidine hydrochloride nasal spray blank preparation.
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
48 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Dexmedetomidine hydrochloride nasal spray compared with placeboDexmedetomidine hydrochloride nasal spray compared with placebo
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Study on Pharmacokinetics and Clinical Efficacy of Dexmedetomidine Hydrochloride Nasal Spray for Preoperative Sedation in Children
Actual Study Start Date :
Jan 6, 2020
Actual Primary Completion Date :
Aug 6, 2020
Actual Study Completion Date :
Aug 7, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: High weight group

High weight group

Drug: Dexmedetomidine hydrochloride nasal spray
In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray. In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray.

Drug: Dexmedetomidine hydrochloride nasal spray blank preparation.
In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation. In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
Other Names:
  • Placebo
  • Experimental: Low weight group

    Low weight group

    Drug: Dexmedetomidine hydrochloride nasal spray
    In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray. In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray.

    Drug: Dexmedetomidine hydrochloride nasal spray blank preparation.
    In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation. In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
    Other Names:
  • Placebo
  • Outcome Measures

    Primary Outcome Measures

    1. PK Cmax [0 to 1 hour after administration]

      Maximum blood concentration (Cmax)

    Secondary Outcome Measures

    1. Proportion of subjects who parent-child separation successful [0 minute to 45 minutes after administration: every 15 minutes after administration]

      The FUNK scale is a scale of 1 to 4 for sedation, anxiety, and separation from parents. Separation success defined as a scale of 3 or 4 per item.

    2. Proportion of subjects who the Ramsay score is satisfactory at least once [0 minute to 45 minutes after administration: every 5 minutes after administration]

      Sedation level using the Ramsay scale. Ramsay Satisfaction defined as a scale of 2, 3, or 4;

    3. Proportion of subjects who the UMSS Scale is satisfactory at least once [0 minute to 45 minutes after administration: every 5 minutes after administration]

      Sedation level using the University of Michigan Sedation Scale. UMSS satisfaction defined as a scale of 3, 4, 5, or 6;

    4. Total consumption of propofol(mg) during general anesthesia [From the beginning of anesthesia to the end of surgical operation up to 4 hours]

      Total consumption of propofol(mg) during general anesthesia

    5. Total consumption of opioid analgesic(μg) during general anesthesia [From the beginning of anesthesia to the end of surgical operation up to 4 hours]

      Total consumption of opioid analgesic(μg) during general anesthesia

    6. Time of anesthesia awakening [Up to 4 hours after the end of surgical operation]

      Time of anesthesia awakening

    7. Proportion of subjects with postoperative agitation [Up to 4 hours after the end of surgical operation]

      Proportion of subjects with postoperative agitation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    2 Years to 6 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Able and willing to provide a written informed consent

    2. Male or female

    3. Subjects requiring elective general anesthesia surgery

    4. Conform to the ASA Physical Status Classification

    5. Meet the weight standard

    Exclusion Criteria:
    1. Not suitable for nasal spray

    2. Pediatric populations requiring special care or court/social welfare supervision

    3. Subjects who had been under general anesthesia were randomized

    4. Subjects with mental disorders and cognitive impairment;Subject with a history of epilepsy

    5. Subjects with previous abnormal behavior after medication

    6. Subjects with cardiovascular disease

    7. Clinically significant abnormal clinical laboratory test value

    8. Subjects whose hemoglobin is below the lower limit of normal

    9. Subjects who have either an adrenergic receptor agonist or an antagonist were randomized

    10. Participated in clinical trials of other drugs before screening (accepted experimental drugs)

    11. A history or possibility of difficult airway

    12. History of hypersensitivity to drug ingredients or components

    13. Other circumstances that the investigator judged inappropriate for participation in this clinical trial

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Beijing children's hospital, capital medical university Beijing Beijing China 100045

    Sponsors and Collaborators

    • Jiangsu HengRui Medicine Co., Ltd.

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jiangsu HengRui Medicine Co., Ltd.
    ClinicalTrials.gov Identifier:
    NCT04200235
    Other Study ID Numbers:
    • HR0171401-102
    First Posted:
    Dec 16, 2019
    Last Update Posted:
    Sep 9, 2020
    Last Verified:
    Nov 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 9, 2020